Skip to main content
SpringerLink
Log in

The Influence of Polypharmacy on Nutrition

  • Chapter
Preventive Nutrition

Part of the book series: Nutrition and Health ((NH))

  • 2506 Accesses

Abstract

There is deservedly much attention being paid to malnutrition and nutrition assessment in clinical practices. Nutrition status may be altered by many things especially in persons with recognized risk factors. High on the list of contributing factors are medications. This chapter will provide a perspective for clinicians on the potential changes to nutrition status resulting from medication use. Many examples from drugs approved in the last 5 years will be provided.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 279.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Slone Epidemiology Center, Boston University. Patterns of medication use in the United States 2006: a report from the Slone Survey. www.bu.edu/slone/files/2012/11/SloneSurveyReport2006.pdf. Accessed Dec 2014.

  2. Kool B, Ameratunga S, Robinson E. Association between prescription medications and falls at home among young and middle-aged adults. Inj Prev. 2012;18:200–3.

    Article  PubMed  Google Scholar 

  3. Gao X, Stephens JM, Carter JA, Haider S, Rustgi VK. Impact of adverse events on costs and quality of life in protease inhibitor-based combination therapy for hepatitis C. Expert Rev Pharmacoecon Outcome Res. 2012;12:335–43.

    Article  Google Scholar 

  4. Shojani KG, Duncan BW, McDonald KM, et al. Making healthcare safer: a critical analysis of patient safety practices. Evidence report/technology assessment No. 43. AHRQ Publication No. 01-E058. Rockville: Agency for Healthcare Research & Quality; 2001.

    Google Scholar 

  5. Public Law No. 109–41, 119 Stat 424 (2005).

    Google Scholar 

  6. Federal Register 2008;73(226):70732–70814.

    Google Scholar 

  7. Jyrkkä J, Enlund H, Lavikainen P, Sulkava R, Hartikainen S. Association of polypharmacy with nutritional status, functional ability and cognitive capacity over a three-year period in an elderly population. Pharmacoepidemiol Drug Saf. 2011;20:514–22.

    Article  PubMed  Google Scholar 

  8. Veehof LJG, Stewart RE, Haaijer-Ruskamp FM, Meyboom-de JB. The development of polypharmacy: a longitudinal study. Fam Pract. 2000;17:261–7.

    Article  PubMed  CAS  Google Scholar 

  9. Moss L, Crane PB. Exploring polypharmacy in elderly women after mycocardial infarction. J Women Aging. 2010;22:22–33.

    Article  PubMed  Google Scholar 

  10. Qato DM, Alexander GC, Conti RM, et al. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA. 2008;300:2867–78.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  11. Heuberger RA, Caudell K. Polypharmacy and nutritional status in older adults: a cross-sectional study. Drugs Aging. 2011;28:315–23.

    Article  PubMed  Google Scholar 

  12. Boullata JI. Drug and nutrition interactions: not just food for thought. J Clin Pharm Ther. 2013;38:269–71.

    Article  PubMed  CAS  Google Scholar 

  13. Lombardi LR, Kreys E, Gerry S, Boullata JI. Nutrition in the age of polypharmacy. In: Bendich A, Deckelbaum RJ, editors. Preventive nutrition. 4th ed. New York: Humana Press; 2010. p. 79–125.

    Chapter  Google Scholar 

  14. Gordon MS, Matei D, Aghajanian C, et al. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol. 2006;24:4324–32.

    Article  PubMed  CAS  Google Scholar 

  15. Agus DB, Sweeney CJ, Morris MJ, et al. Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy. J Clin Oncol. 2007;25:675–81.

    Article  PubMed  CAS  Google Scholar 

  16. Race TF, Paes IC, Faloon WW. Intestinal malabsorption induced by oral colchicines: comparison with neomycin and cathartic agents. Am J Med Sci. 1970;259:32–41.

    Article  PubMed  CAS  Google Scholar 

  17. Jacobson ED, et al. Depletion of vitamin B12, iron, beta-carotene, and fat malabsorptive effects of neomycin in commonly used doses. JAMA. 1961;175:187–90.

    Article  PubMed  CAS  Google Scholar 

  18. Moore AR, O’Keeffe ST. Drug-induced cognitive impairment in the elderly. Drugs Aging. 1999;15:15–28.

    Article  PubMed  CAS  Google Scholar 

  19. Leucht S, Komossa K, Rummel-Kluge C, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry. 2009;166:152–63.

    Article  PubMed  Google Scholar 

  20. Almandil NB, Liu Y, Murray ML, et al. Weight gain and other metabolic adverse effects associated with atypical antipsychotic treatment of children and adolescents: a systematic review and meta-analysis. Pediatr Drugs. 2013;15:139–50.

    Article  Google Scholar 

  21. Mankal PK, Kotler DP. From wasting to obesity, changes in nutritional concerns in HIV/AIDS. Endocrinol Metab Clin N Am. 2014;43:647–63.

    Article  Google Scholar 

  22. Roe DA. Drug effects on nutrient absorption, transport, and metabolism. Drug Nutr Interact. 1985;4:117–35.

    PubMed  CAS  Google Scholar 

  23. Biehl JP, Vilter RW. Effects of isoniazid on pyridoxine metabolism. JAMA. 1954;156:1549–52.

    Article  CAS  Google Scholar 

  24. Shin HC, Landowski CP, Sun D, et al. Transporters in the GI tract. In: van de Waterbeemd H, Lennernäs H, Artursson P, editors. Drug bioavailability: estimation of solubility, permeability, absorption and bioavailability. Weinheim: Wiley; 2003. p. 245–87.

    Google Scholar 

  25. Rønnestad I, Akiba Y, Kaji I, Kaunitz JD. Duodenal luminal nutrient sensing. Curr Opin Pharmacol. 2014;19:67–75.

    Article  PubMed  CAS  Google Scholar 

  26. Efeyan A, Comb WC, Sabatini DM. Nutrient sensing mechanisms and pathways. Nature. 2015;517:302–10.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  27. Boullata JI, Hudson LM. Drug-nutrient interactions: a broad view with implications for practice. J Acad Nutr Diet. 2012;112:506–17.

    Article  PubMed  Google Scholar 

  28. Said HM, Redha R, Nylander W. Biotin transport in the human intestine: inhibition by anticonvulsant drugs. Am J Clin Nutr. 1989;49:127–31.

    PubMed  CAS  Google Scholar 

  29. Mock DM, Dyken ME. Biotin catabolism is accelerated in adults receiving long-term therapy with anticonvulsants. Neurology. 1997;49:1444–7.

    Article  PubMed  CAS  Google Scholar 

  30. Lambie DG, Johnson RH. Drugs and folate metabolism. Drugs. 1985;30:145–55.

    Article  PubMed  CAS  Google Scholar 

  31. Frequin ST, Wevers RA, Braam M, et al. Decreased vitamin B12 and folate levels in cerebrospinal fluid and serum of multiple sclerosis patients after high-dose intravenous methylprednisolone. J Neurol. 1993;240:305–8.

    Article  PubMed  CAS  Google Scholar 

  32. Peretz A, Neve J, Vertongen F, et al. Selenium status in relation to clinical variables and corticosteroid treatment in rheumatoid arthritis. J Rheumatol. 1987;14:1104–7.

    PubMed  CAS  Google Scholar 

  33. Ruze P. Kava-induced dermopathy: a niacin deficiency? Lancet. 1990;335:1442–5.

    Article  PubMed  CAS  Google Scholar 

  34. U.S. Food and Drug Administration. FDA approved drug product information with access to approved labeling. http://www.fda.gov/Drugs/default.htm. Accessed Dec 2014.

  35. National Cancer Institute: Cancer Therapy Evaluation Program. Common terminology for adverse events (CTCAE) v 4.0, May 2010. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40, Accessed Mar 2015.

  36. McDonald S, Clements JN. Dalfampridine: a new agent for symptomatic management of multiple sclerosis. Am J Health Syst Pharm. 2011;68:2335–40.

    Article  PubMed  CAS  Google Scholar 

  37. Holtmann G, Talley NJ. The stomach-brain axis. Best Pract Res Clin Gastroenterol. 2014;28:967–79.

    Article  PubMed  CAS  Google Scholar 

  38. Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424–33.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  39. Margolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 2012;13:459–65.

    Article  PubMed  CAS  Google Scholar 

  40. Kwon ED, Drake CG, Scher HI, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 study. Lancet Oncol. 2014;15:700–12.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  41. Siniscalchi A, Gallelli L, Russo E, De Sarro G. A review on antiepileptic drugs-dependent fatigue: pathophysiological mechanisms and incidence. Eur J Pharmacol. 2013;718:10–6.

    Article  PubMed  CAS  Google Scholar 

  42. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995–2005.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Qin H, Li H, Zhou X, et al. Safety of telaprevir for chronic hepatitis C virus infection: a meta-analysis of randomized controlled trials. Clin Drug Investig. 2012;32:665–72.

    Article  PubMed  CAS  Google Scholar 

  44. Cortes J, Digumarti R, Parikh PM, et al. Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors. Am J Hematol. 2013;88:350–4.

    Article  PubMed  CAS  Google Scholar 

  45. Chung C. Omacetaxine for treatment-resistant or treatment-intolerant adult chronic myeloid leukemia. Am J Health Syst Pharm. 2014;71:279–88.

    Article  PubMed  CAS  Google Scholar 

  46. Ellis PM, Jungnelius U, Zhang J, et al. A phase I study of pomalidomide (CC-4047) in combination with cisplatin and etoposide in patients with extensive-stage small-cell lung cancer. J Thorac Oncol. 2013;8:423–8.

    Article  PubMed  CAS  Google Scholar 

  47. Eisen T, Joensuu H, Nathan PD, et al. Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial. Lancet Oncol. 2012;13:1055–62.

    Article  PubMed  CAS  Google Scholar 

  48. Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381:303–12.

    Article  PubMed  CAS  Google Scholar 

  49. Bruix J, Tak W-Y, Gasbarrini A, et al. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma multicentre, open-label, phase II safety study. Eur J Cancer. 2013;49:3412–9.

    Article  PubMed  CAS  Google Scholar 

  50. Jagannath S, Vij R, Stewart AK, et al. An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma. Clin Lymph Myel Leuk. 2012;12:310–8.

    Article  CAS  Google Scholar 

  51. Siegel D, Martin T, Nooka A, et al. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica. 2013;98:1753–61.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  52. Fennira F, Pagès C, Schneider P, et al. Vemurafenib in the French temporary authorization for use metastatic melanoma cohort: a single centre trial. Melanoma Res. 2014;24:75–82.

    Article  PubMed  CAS  Google Scholar 

  53. Larkin J, Del Vecchio M, Ascierto PA, et al. Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicenter, safety study. Lancet Oncol. 2014;15:436–44.

    Article  PubMed  CAS  Google Scholar 

  54. Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369:507–16.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  55. O’Brien S, Furman RR, Coutre SE, et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicenter, phase 1b/2 trial. Lancet Oncol. 2014;15:48–58.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  56. Proctor AE, Thompson LA, O’Bryant CL. Vismodegib: an inhibitor of the hedgehog signaling pathway in the treatment of basal cell carcinoma. Ann Pharmacother. 2014;48:99–106.

    Article  PubMed  CAS  Google Scholar 

  57. Fruehauf J, Lutzky J, McDermott D, et al. Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma. Clin Cancer Res. 2011;17:7462–9.

    Article  PubMed  CAS  Google Scholar 

  58. Fujiwara Y, Kiyota N, Chayahara N, et al. Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients. Invest New Drugs. 2012;30:1055–64.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  59. Ueda T, Uemura H, Tomita Y, et al. Efficacy and safety of axitinib versus sorafenib in metastatic renal carcinoma: subgroup analysis of Japanese patients from the global randomized phase 3 AXIS trial. Jpn J Clin Oncol. 2013;43:616–28.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Bennett LL, Ingason A. Enzalutamide (Xtandi) for patients with metastatic, resistant prostate cancer. Ann Pharmacother. 2014;48:530–7.

    Article  PubMed  CAS  Google Scholar 

  61. French JA, Abou-Khalil BW, Leroy RF, et al. Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy. Neurology. 2011;76:1555–63.

    Article  PubMed  CAS  Google Scholar 

  62. Gidal BE, Ferry J, Majid O, Hussein Z. Concentration-effect relationships with perampanel in patients with pharmacoresistant partial onset seizures. Epilepsia. 2013;54:1490–7.

    Article  PubMed  CAS  Google Scholar 

  63. Wolin EM, Hu K, Hughes G, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of a long-acting release (LAR) formulation of pasireotide (SOM230) in patients with gastroenteropancreatic neuroendocrine tumors: results from a randomized, multicenter, open-label, phase I study. Cancer Chemother Pharmacol. 2013;72:387–95.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  64. Byrd JC, Brown JR, O’Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371:213–23.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  65. Gervasio JM. Drug-induced changes to nutritional status. In: Boullata JI, Armenti VT, editors. Handbook of drug-nutrient interactions. 2nd ed. New York: Humana Press; 2010. p. 427–45.

    Google Scholar 

  66. Cirrone F, Harris CS. Vismodegib and the Hedgehog pathway: a new treatment for basal cell carcinoma. Clin Ther. 2012;34:2039–50.

    Article  PubMed  CAS  Google Scholar 

  67. Kaye SB, Fehrenbacher L, Holloway R, et al. A phase II, randomized, placebo-controlled study of vismodegib as maintenance therapy in patients with ovarian cancer in second or third complete remission. Clin Cancer Res. 2012;18:6509–18.

    Article  PubMed  CAS  Google Scholar 

  68. Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366:2171–9.

    Article  PubMed  CAS  Google Scholar 

  69. Katakami N, Atagi S, Goto K, et al. LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gemfitinib, or both. J Clin Oncol. 2013;31:3335–41.

    Article  PubMed  CAS  Google Scholar 

  70. Machado PR, Ampuero J, Guimarães LH, et al. Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial. PLoS Negl Tropical Dis. 2010;4, e912.

    Article  Google Scholar 

  71. Chrusciak-Talhari A, Dietze R, Talhari CC, et al. Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania (Viannia) guyanensis in Manaus. Brazil Am J Trop Med Hyg. 2011;84:255–60.

    Article  PubMed  CAS  Google Scholar 

  72. Xu XS, Etropolski M, Upmalis D, et al. Pharmacokinetic and pharmacodynamics modeling of opioid-induced gastrointestinal side effects in patient receiving tapentadol IR and oxycodone IR. Pharm Res. 2012;29:2555–64.

    Article  PubMed  CAS  Google Scholar 

  73. Steigerwald I, Schenk M, Lahne U, et al. Effectiveness and tolerability of tapentadol prolonged release compared with prior opioid therapy for the management of severe, chronic osteoarthritis pain. Clin Drug Invest. 2013;33:607–19.

    Article  CAS  Google Scholar 

  74. Beglinger C, Hu K, Wang Y, et al. Multiple once-daily subcutaneous doses of pasireotide were well tolerated in healthy male volunteers: a randomized, double-blind, placebo-controlled, cross-over, Phase I study. Endocrine. 2012;42:366–74.

    Article  PubMed  CAS  Google Scholar 

  75. Kvols LK, Oberg KE, O’Dorisio TM, et al. Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study. Endocr Rel Cancer. 2012;19:657–66.

    Article  CAS  Google Scholar 

  76. Favrat B, Balck K, Breymann C, et al. Evaluation of a single dose of ferric carboxymaltose in fatigued, iron-deficient women—PREFER a randomized, placebo-controlled study. PLoS One. 2014;9, e94217.

    Article  PubMed  PubMed Central  Google Scholar 

  77. Lyseng-Williamson KA, Keating GM. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia. Drugs. 2009;69:739–56.

    Article  PubMed  CAS  Google Scholar 

  78. Anderson SD, Shah NK, Yim J, Epstein BJ. Efficacy and safety of ticagrelor: a reversible P2Y12 receptor antagonist. Ann Pharmacother. 2010;44:524–37.

    Article  PubMed  CAS  Google Scholar 

  79. Lean MEJ, Carraro R, Finer N, et al. Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults. Int J Obes. 2014;38:689–97.

    Article  CAS  Google Scholar 

  80. Robinson DS, Kajdasz DK, Gallipoli S, et al. A 1-year, open-label study assessing the safety and tolerability of vilazodone in patients with major depressive disorder. J Clin Psychopharmacol. 2011;31:643–6.

    PubMed  CAS  Google Scholar 

  81. Choi E, Zmarlicka M, Ehret MJ. Vilazodone: a novel antidepressant. Am J Health Syst Pharm. 2012;69:1551–7.

    Article  PubMed  CAS  Google Scholar 

  82. Citrome L. Levomilnacipran for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant. Int J Clin Pract. 2013;67:1089–104.

    Article  PubMed  CAS  Google Scholar 

  83. Sambunaris A, Bose A, Gommoll CP, Chen C, Greenberg WM, Sheehan DV. A phase-III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorder. J Clin Psychopharmacol. 2014;34:47–56.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  84. Kappos L, Gold R, Miller DH, et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, placebo-controlled phase IIb study. Lancet. 2008;372:1463–72.

    Article  PubMed  CAS  Google Scholar 

  85. Gold R, Kappos L, Arnold DL, et al. Placebo-controlled, phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367:1098–107.

    Article  PubMed  CAS  Google Scholar 

  86. Cortes JE, Kim D-W, Pinilla-Ibarz J, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369:1783–96.

    Article  PubMed  CAS  Google Scholar 

  87. Dy EA, Shiltz DL. Hemopericardium and cardiac tamponade associated with dabigatran use. Ann Pharmacother. 2012;46, e18.

    Article  PubMed  Google Scholar 

  88. Fellows SE, Rosini JM, Curtis JA, Volz EG. Hemorrhagic gastritis with dabigatran in a patient with renal insufficiency. J Emerg Med. 2013;44:e221–5.

    Article  PubMed  Google Scholar 

  89. Bytzer P, Connolly SJ, Yang S, et al. Analysis of upper gastrointestinal adverse events among patients given dabigatran in the RE-LY trial. Clin Gastroenterol Hepatol. 2013;11:246–52.

    Article  PubMed  CAS  Google Scholar 

  90. Bolesta S, Montgomery PA. Pancreatitis. In: Dipiro JT, editor. Pharmacotherapy: a pathophysiologic approach. 9th ed. New York: McGraw-Hill; 2014. p. 565–81.

    Google Scholar 

  91. Monami M, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2014;16:48–56.

    Article  PubMed  CAS  Google Scholar 

  92. Franks AS, Lee PH, George CM. Pancreatitis: a potential complication of liraglutide? Ann Pharmacother. 2012;46:1547–53.

    Article  PubMed  CAS  Google Scholar 

  93. Knezevich E, Crnic T, Kershaw S, Drincic A. Liraglutide-associated acute pancreatitis. Am J Health Syst Pharm. 2012;69:386–9.

    Article  PubMed  CAS  Google Scholar 

  94. Monami M, Dicembrini I, Nardini C, Fiordelli I, Mannucci E. Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials. Diab Res Clin Pract. 2014;103:269–75.

    Article  CAS  Google Scholar 

  95. Fabel PH, Shealy KM. Diarrhea, constipation and irritable bowel syndrome. In: DiPiro JT, editor. Pharmacotherapy: a pathophysiologic approach. 9th ed. New York: McGraw-Hill; 2014. p. 531–47.

    Google Scholar 

  96. Lembo AJ, Kurtz CB, MacDougall JE, et al. Efficacy of linaclotide for patients with chronic constipation. Gastroenterology. 2010;138:886–95.

    Article  PubMed  CAS  Google Scholar 

  97. Lembo AJ, Schneier HA, Shiff SJ, et al. Two randomized trials of linaclotide for chronic constipation. N Engl J Med. 2011;365:527–36.

    Article  PubMed  CAS  Google Scholar 

  98. Chey WD, Lembo AJ, Lavins BJ, et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol. 2012;107:1702–12.

    Article  PubMed  CAS  Google Scholar 

  99. Rao SSC, Quigley EMM, Shiff SJ, et al. Effect of linaclotide on severe abdominal symptoms in patients with irritable bowel syndrome with constipation. Clin Gastroenterol Hepatol. 2014;12:616–23.

    Article  PubMed  CAS  Google Scholar 

  100. Papp K, Cather JC, Rosoph L, et al. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. Lancet. 2012;380:738–46.

    Article  PubMed  CAS  Google Scholar 

  101. Baselga J, Cortés J, Kim S-B, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366:109–19.

    Article  PubMed  CAS  Google Scholar 

  102. Li H, Fu W, Gao X, et al. Risk of severe diarrhea with dual anti-HER2 therapies: a meta-analysis. Tumor Biol. 2014;35:4077–85.

    Article  CAS  Google Scholar 

  103. Timm A, Kolesar JM. Crizotinib for the treatment of non-small-cell lung cancer. Am J Health Syst Pharm. 2013;70:943–7.

    Article  PubMed  CAS  Google Scholar 

  104. Solomon BJ, Mok T, Kim D-W, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371:2167–77.

    Article  PubMed  CAS  Google Scholar 

  105. Shaw AT, Kim D-W, Mehra R, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med. 2014;370:1189–97.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  106. Abbas R, Hug BA, Leister C, et al. A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects. Cancer Chemother Pharmacol. 2012;69:221–7.

    Article  PubMed  CAS  Google Scholar 

  107. Kantarjian HM, Cortes JE, Kim D-W, et al. Bosutinib safety and management of toxicity in leukemia patients with resistance to imatinib and other tyrosine kinase inhibitors. Blood. 2014;123:1309–18.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  108. Gambacorti-Passerini C, Brümmendorf TH, Kim D-W, et al. Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: minimum 24-month follow-up. Am J Hematol. 2014;89:732–42.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  109. Elisei R, Schlumberger MJ, Müller SP, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013;31:3639–46.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  110. Lee JS, Hirsh V, Park K, et al. Vandetanib versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR). J Clin Oncol. 2012;30:1114–21.

    Article  PubMed  CAS  Google Scholar 

  111. Ton GN, Banaszynski ME, Kolesar JM. Vandetanib: a novel targeted therapy for the treatment of metastatic or locally advanced medullary thyroid cancer. Am J Health Syst Pharm. 2013;70:849–55.

    Article  PubMed  CAS  Google Scholar 

  112. Larkin J, Fishman M, Wood L, et al. Axitinib for the treatment of metastatic renal cell carcinoma: recommendations for therapy management to optimize outcomes. Am J Clin Oncol. 2014;37:397–403.

    Article  PubMed  CAS  Google Scholar 

  113. Chopra A, Klein PL, Drinnan T, Lee SS. How to optimize HCV therapy in genotype 1 patients: management of side effects. Liver Int. 2013;33:30–4.

    Article  PubMed  CAS  Google Scholar 

  114. Wilcox MH, Corey GR, Talbot GH, et al. CANVAS 2: the second phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infection. J Antimicrob Chemother. 2010;65:53–65.

    Article  CAS  Google Scholar 

  115. File TM, Low DE, Eckburg PB, et al. FOCUS 1: a randomized, double-blinded, multicenter, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother. 2011;66:19–32.

    Article  CAS  Google Scholar 

  116. Mitchell KA, Kluger H, Sznol M, Hartman DJ. Ipilimumab-induced perforating colitis. J Clin Gastroenterol. 2013;47:781–5.

    Article  PubMed  Google Scholar 

  117. Dilling P, Walczak J, Pikiel P, Kruszewski WJ. Multiple colon perforation as a fatal complication during treatment of metastatic melaonoma with ipilimumab: case report. Pol Przegl Chir. 2014;86:94–6.

    PubMed  Google Scholar 

  118. Usiskin K, Kline I, Fung A, Mayer C, Meininger G. Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results. Postgrad Med. 2014;126(3):16–34.

    Article  PubMed  Google Scholar 

  119. Engelen MA, Welp HA, Gunia S, et al. Prospective study of everolimus with calcineurin inhibitor-free immunosuppression after heart transplantation: results at four years. Ann Thorac Surg. 2014;97:888–93.

    Article  PubMed  Google Scholar 

  120. Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13:983–92.

    Article  PubMed  CAS  Google Scholar 

  121. Chou K, Perry CM. Metreleptin: first global approval. Drugs. 2013;73:989–97.

    Article  PubMed  CAS  Google Scholar 

  122. Moon H-S, Matarese G, Brennan AM, et al. Efficacy of metreleptin in obese patients with type 2 diabetes: cellular and molecular pathways underlying leptin tolerance. Diabetes. 2011;60:1647–56.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  123. Shetty GK, Matarese G, Magkos F, et al. Leptin administration to overweight and obese subjects for 6 months increases free leptin concentrations but does not alter circulating hormones of the thyroid and IGF axes during weight loss induced by a mild hypocaloric diet. Eur J Endocrinol. 2011;165:249–54.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  124. Hurren KM, Berlie HD. Lorcaserin: an investigational serotonin 2C agonist for weight loss. Am J Health Syst Pharm. 2011;68:2029–37.

    Article  PubMed  CAS  Google Scholar 

  125. Zheng J, Yang J, Zhou X, et al. Roflumilast for the treatment of COPD in an Asian population: a randomized, double-blind, parallel-group study. Chest. 2014;145:44–52.

    Article  PubMed  CAS  Google Scholar 

  126. Tashkin DP. Roflumilast: the new orally active, selective phosphodiesterase-4 inhibitor, for the treatment of COPD. Expert Opin Pharmacother. 2014;15:85–96.

    Article  PubMed  CAS  Google Scholar 

  127. De Hert M, Yu W, Detraux J, et al. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis. CNS Drugs. 2012;26:733–59.

    Article  PubMed  Google Scholar 

  128. Citrome L, Ketter TA, Cucchiaro J, Loebel A. Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed. J Affect Disord. 2014;155:20–7.

    Article  PubMed  CAS  Google Scholar 

  129. Krauss GL, Perucca E, Ben-Menachem E, et al. Long-term safety of perampanel and seizure outcomes in refractory partial-onset seizures and secondarily generalized seizures: results from phase III extension study 307. Epilepsia. 2014;55:1058–68.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  130. Ji L, Ma J, Li H, et al. Dapagliflozin as monotherapy in drug-naïve Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study. Clin Ther. 2014;36:84–100.

    Article  PubMed  CAS  Google Scholar 

  131. Ptaszynska A, Hardy E, Johnsson E, Parikh S, List J. Effects of dapagliflozin on cardiovascular risk factors. Postgrad Med. 2013;125:181–9.

    Article  PubMed  Google Scholar 

  132. Park H, Park C, Kim Y, Rascati KL. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes: meta-analysis. Ann Pharmacother. 2012;46:1453–69.

    Article  PubMed  CAS  Google Scholar 

  133. Alegre C, Jiménez C, Manrique A, et al. Everolimus monotherapy or combined therapy in liver transplantation: indications and results. Transplant Proc. 2013;45:1971–4.

    Article  PubMed  CAS  Google Scholar 

  134. Uchida J, Machida Y, Iwai T, et al. Conversion of stable ABO-incompatible kidney transplant recipients from mycophenolate mofetil with standard exposure calcineurin inhibitors (CNIs) to everolimus with very low exposure CNIs: a short-term pilot study. Clin Transplant. 2014;28:80–7.

    Article  PubMed  CAS  Google Scholar 

  135. Singh JA, Beg S, Lopez-Olivo MA. Tocilizumab for rheumatoid arthritis: a Cochran systematic review. J Rheumatol. 2011;38:10–20.

    Article  PubMed  Google Scholar 

  136. Strang AC, Bisoendial RJ, Kootte RS, et al. Pro-atherogenic lipid changes and decreased hepatic LDL receptor expression by tocilizumab in rheumatoid arthritis. Atherosclerosis. 2013;229:174–81.

    Article  PubMed  CAS  Google Scholar 

  137. Younis S, Rosner I, Rimar D, et al. Weight change during pharmacological blockade of interleukin-6 or tumor necrosis factor-α in patients with inflammatory rheumatic disorders: a 16-week comparative study. Cytokine. 2013;61:353–5.

    Article  PubMed  CAS  Google Scholar 

  138. Kurzrock R, Voorhees PM, Casper C, et al. A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. Clin Cancer Res. 2013;19:3659–70.

    Article  PubMed  CAS  Google Scholar 

  139. Lam S. Azilsartan: a newly approved angiotensin II receptor blocker. Cardiol Rev. 2011;19:300–4.

    Article  PubMed  Google Scholar 

  140. Gelsinger C, Steinhagen-Thiessen E, Kassner U. Therapeutic potential of mipomersen in the management of familial hypercholesterolaemia. Drugs. 2012;72:1445–55.

    Article  PubMed  CAS  Google Scholar 

  141. Dhillon S. Tesmorelin: a review of its use in the management of HIV-associated lipodystrophy. Drugs. 2011;71:1071–91.

    Article  PubMed  CAS  Google Scholar 

  142. Wiseman AC, McCague K, Kim Y, Geissler F, Cooper M. The effect of everolimus versus mycophenolate upon proteinuria following kidney transplant and relationship to graft outcomes. Am J Transplant. 2013;13:442–9.

    Article  PubMed  CAS  Google Scholar 

  143. Miura M, Yanai M, Fukasawa Y, Higashiyama H, Ito Y, Tamaki T. De novo proteinuria with pathological evidence of glomerulonephritis after everolimus induction. Nephrology (Carlton). 2014;19 Suppl 3:57–9.

    Article  Google Scholar 

  144. Shihab FS, Cibrik D, Chan L, et al. Association of clinical events with everolimus exposure in kidney transplant patients receiving reduced cyclosporine. Clin Transplant. 2013;27:217–26.

    Article  PubMed  CAS  Google Scholar 

  145. Hu B, Chen Y, Usmani SZ, et al. Characterization of the molecular mechanisms of the bone-anabolic activity of carfilzomib in multiple myeloma. PLoS One. 2013;8, e74191.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  146. Mirbehbahani N, Jahazi A, Abad HHNR. The effect of combined therapy with deferoxamine and deferiprone on serum ferritin level of beta-thalassemic patients. Hematology. 2012;17:183–6.

    Article  PubMed  CAS  Google Scholar 

  147. Erdoğan E, Canatan D, Örmeci AR, Vural H, Aylak F. The effects of chelators on zinc levels in patients with thalassemia major. J Trace Elem Med Biol. 2013;27:109–11.

    Article  PubMed  CAS  Google Scholar 

  148. Bartlett NL, Chen R, Fanale MA, et al. Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. J Hematol Oncol. 2014;7:24.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  149. Gambacorti-Passerini C, Cortes JE, Lipton JH, et al. Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia. Am J Hematol. 2014;89:947–53.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  150. Shely RN, Ratliff PD. Carflizomib-associated tumor lysis syndrome. Pharmacotherapy. 2014;34:e34–7.

    Article  PubMed  CAS  Google Scholar 

  151. Chawla S, Henshaw R, Seeger L, et al. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of the bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol. 2013;14:901–8.

    Article  PubMed  CAS  Google Scholar 

  152. Lechner B, DeAngelis C, Jamal N, et al. The effects of denosumab on calcium profiles in advanced cancer patients with bone metastases. Supp Care Cancer. 2014;22:1765–71.

    Article  Google Scholar 

  153. Okada N, Kawazoe K, Teraoka K, et al. Identification of the risk factors associated with hypocalcemia induced by denosumab. Biol Pharm Bull. 2013;36:1622–6.

    Article  PubMed  CAS  Google Scholar 

  154. Trinh VA, Davis JE, Anderson JE, Kim KB. Dabrafenib therapy for advanced melanoma. Ann Pharmacother. 2014;48:519–29.

    Article  PubMed  CAS  Google Scholar 

  155. Ning YM, Pierce W, Maher VE, et al. Enzalutamide for treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel. Clin Cancer Res. 2013;19:6067–73.

    Article  PubMed  CAS  Google Scholar 

  156. LaPointe NE, Morfini G, Brady ST, Feinstein FC, Wilson L, Jordan MA. Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: implications for chemotherapy-induced peripheral neuropathy. Neurotoxicology. 2013;37:231–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  157. Vahdat LT, Garcia AA, Vogel C, et al. Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized phase II study comparing the incidence of peripheral neuropathy. Breast Cancer Res Treat. 2013;140:341–51.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  158. Zinzani PL, Viviani S, Anastasia A, et al. Brentuximab vedotin in relapsed/refractory Hodgkin’s lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials. Haematologica. 2013;98:1232–6.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  159. Schloss JM, Colosimo M, Airey C, Masci PP, Linnane AW, Vitetta L. Nutraceuticals and chemotherapy induced peripheral neuropathy (CIPN): a systematic review. Clin Nutr. 2013;32:888–93.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Nutrition Support Services, Hospital of the University of Pennsylvania, 34th & Spruce Streets, Philadelphia, PA, 19104, USA

    Korinne M. Piccolo M.A., R.D., CNSC, LDN

  2. University of Pennsylvania, 418 Curie Boulevard, Philadelphia, PA, 19104, USA

    Joseph I. Boullata Pharm.D.,R.Ph.,BCNSP,FASPEN,FACN

Authors
  1. Korinne M. Piccolo M.A., R.D., CNSC, LDN
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joseph I. Boullata Pharm.D.,R.Ph.,BCNSP,FASPEN,FACN
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Korinne M. Piccolo M.A., R.D., CNSC, LDN or Joseph I. Boullata Pharm.D.,R.Ph.,BCNSP,FASPEN,FACN .

Editor information

Editors and Affiliations

  1. Consultants in Consumer Healthcare, Morristown, New Jersey, USA

    Adrianne Bendich

  2. Columbia University Inst. Human Nutrition, New York, New York, USA

    Richard J. Deckelbaum

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Piccolo, K.M., Boullata, J.I. (2015). The Influence of Polypharmacy on Nutrition. In: Bendich, A., Deckelbaum, R. (eds) Preventive Nutrition. Nutrition and Health. Springer, Cham. https://doi.org/10.1007/978-3-319-22431-2_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-22431-2_6

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-22430-5

  • Online ISBN: 978-3-319-22431-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation